Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Fertility
Interventions
PROCEDURE

Self administration

Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).

Trial Locations (2)

33617

Planned Parenthood of Southwest and Central Florida, Tampa

33919

Planned Parenthood of Southwest and Central Florida, Fort Myers

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Planned Parenthood Federation of America

OTHER

lead

University of North Carolina, Chapel Hill

OTHER